In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot. Gene-editing is not just science but rewriting life itself. For clinical-stage companies, one successful trial can mean validation, funding, and survival, while one failure can send years of research crashing down overnight.
That’s exactly what happened with Intellia Therapeutics (NTLA). Once a rising star in CRISPR innovation, the company’s story took a tragic turn when an elderly patient in the firm's MAGNITUDE Phase III trial passed away following severe liver complications. The patient, dosed with Intellia’s therapy candidate nexiguran ziclumeran (nex-z), showed elevated enzyme levels weeks after treatment. The U.S. Food and Drug Administration (FDA) swiftly imposed a full clinical hold, halting both MAGNITUDE studies and shaking confidence across the gene-editing world.
